What Is Humira (Adalimumab)?
Humira was once the world's best-selling drug — a distinction it held for years before its patents began to expire and biosimilar competitors entered the market. The active ingredient, adalimumab, is a fully human monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), a key inflammatory protein involved in numerous immune-mediated diseases. Understanding Humira means understanding how the immune system can be selectively disrupted to treat conditions ranging from rheumatoid arthritis to Crohn's disease to pediatric plaque psoriasis.
The Mechanism: Blocking TNF-Alpha
TNF-alpha is a cytokine — a signaling protein — produced primarily by macrophages and T cells. In healthy immune function, it coordinates inflammatory responses against pathogens. In autoimmune and inflammatory diseases, TNF-α is overproduced and drives chronic, destructive inflammation in joints, the gastrointestinal tract, skin, and other tissues.
Adalimumab is a large IgG1 antibody that binds with high specificity to both soluble and membrane-bound TNF-α, neutralizing it before it can bind to its receptors on target cells. Unlike the first TNF inhibitor approved (infliximab, a chimeric mouse-human antibody), adalimumab is fully human — meaning it was produced using phage display technology to generate a human antibody sequence, which theoretically reduces the immunogenicity (the risk that the immune system will develop antibodies against the drug itself).
FDA-Approved Indications
| Indication | Adult/Pediatric |
|---|---|
| Rheumatoid arthritis (moderate-to-severe) | Adults |
| Juvenile idiopathic arthritis | Pediatric (≥2 years) |
| Psoriatic arthritis | Adults |
| Ankylosing spondylitis | Adults |
| Plaque psoriasis (moderate-to-severe) | Adults + Pediatric (≥4 years) |
| Crohn's disease (moderate-to-severe) | Adults + Pediatric (≥6 years) |
| Ulcerative colitis (moderate-to-severe) | Adults + Pediatric (≥5 years) |
| Hidradenitis suppurativa (moderate-to-severe) | Adults + Adolescents (≥12 years) |
| Non-infectious intermediate, posterior, and panuveitis | Adults + Pediatric (≥2 years) |
Biosimilars: The Competitive Landscape Since 2023
AbbVie's Humira patent exclusivity expired in the United States in 2023, opening the market to biosimilar adalimumab products — highly similar but not identical copies of the original biologic. This was one of the most anticipated biosimilar launches in pharmaceutical history given Humira's market dominance.
Multiple adalimumab biosimilars have received FDA approval, including Hadlima (Samsung Bioepis/Organon), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Amjevita (Amgen), Hulio (Mylan/Fujifilm), Yusimry (Coherus), and others. Many are available in citrate-free, high-concentration formulations similar to Humira's own citrate-free version, which was introduced to reduce injection-site pain. Biosimilars have meaningfully reduced list prices for adalimumab, though the actual cost to patients depends heavily on insurer formulary decisions and manufacturer rebate arrangements.
Black Box Warnings
SERIOUS INFECTIONS: TNF inhibitors suppress immune function and increase the risk of serious, sometimes fatal infections including bacterial sepsis, invasive fungal infections (histoplasmosis, coccidioidomycosis, aspergillosis), and infections due to opportunistic pathogens. Humira is contraindicated during active infection. TB screening (tuberculin skin test or IGRA blood test) is required before starting Humira — latent TB can reactivate and become life-threatening under TNF inhibition.
MALIGNANCY: Lymphomas and other malignancies — some fatal — have been reported in patients treated with TNF blockers, primarily in children and adolescents. The role of TNF inhibitors in malignancy risk (vs. underlying disease) is difficult to fully disentangle, but the warning requires a careful risk-benefit discussion, particularly in patients with a prior history of malignancy.
Common Side Effects
- Injection site reactions: Pain, redness, itching, or swelling at the injection site are the most common side effects, affecting a significant percentage of patients. Citrate-free formulations help reduce stinging.
- Upper respiratory infections: Sinusitis, pharyngitis, and nasopharyngitis occur at increased rates due to immune suppression.
- Headache: Reported frequently in clinical trials.
- Rash: Various skin reactions including rash and eczema have been reported.
- Paradoxical psoriasis: Some patients develop new or worsening psoriasis while on TNF inhibitors — a counterintuitive effect that may represent an immune dysregulation response.
Cost Considerations
Humira's annual list price before biosimilar competition was in the range of $70,000–$84,000 per year. Biosimilars have been launched at meaningful discounts off Humira's list price. Actual patient out-of-pocket cost depends on insurance, copay assistance programs (AbbVie offers myAbbVie Assist for uninsured/underinsured patients), and formulary placement. Patients should consult with their insurer and specialty pharmacy to understand their specific cost exposure.
Want to compare Humira to biosimilars or other biologics for your condition?
Compare MedicationsFrequently Asked Questions
Humira (adalimumab) is approved for multiple inflammatory and autoimmune conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and uveitis. It works by blocking tumor necrosis factor-alpha (TNF-α), a protein that drives chronic inflammation in these diseases. Several indications extend to pediatric populations as young as 2 years old.
No. Humira is a biologic medication — a large, protein-based drug (monoclonal antibody) — not a steroid. Steroids like prednisone work by broadly suppressing the immune system through glucocorticoid receptors. Adalimumab works by targeting a single specific inflammatory protein (TNF-α). This targeted approach means it does not carry the same metabolic and hormonal side effects associated with long-term steroid use, though it does carry its own risks, particularly around infection.
Biosimilars are medications that are highly similar to an approved biologic (the "reference product") and have no clinically meaningful differences in safety, purity, or potency. Humira biosimilars include Hadlima, Hyrimoz, Cyltezo, Amjevita, Hulio, Yusimry, and others. The FDA requires rigorous demonstration of biosimilarity before approval. Biosimilars offer the potential for lower costs, though list price discounts have not always translated into equivalent savings at the pharmacy counter due to complex rebate structures.